Zion, ILNCT07484022Now EnrollingIRB Ready

Advanced Urothelial Cancer Clinical Trial in Zion, IL

Access cutting-edge advanced urothelial cancer treatment through this clinical trial at a research site in Zion. Study-provided care at no cost to qualified participants.

Sponsored by Generate Biomedicines

Quick Self-Assessment

See if you qualify for this Zion location

Preparing your pre-screening questions…

Expert Care in Zion

Access advanced urothelial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced urothelial cancer treatment provided free

Apply for This Zion Location

Check if you qualify for this advanced urothelial cancer clinical trial in Zion, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Zion

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Zion site if eligible
  4. 4Begin participation

About This Advanced Urothelial Cancer Study in Zion

The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.

Sponsor: Generate Biomedicines

Who Can Participate

Inclusion Criteria

Planned to receive standard-of-care treatment with enfortumab vedotin (EV) (starting dose 1.25 mg/kg) in combination with pembrolizumab for locally advanced or metastatic urothelial cancer.
Age ≥18 years.
ECOG Performance Status score of 0 or 1 (ECOG 2 excluded in Dose Escalation but allowed in Dose Expansion).
Weight ≥50 kg at screening.
Life expectancy ≥3 months, as determined by the investigator.
Participants must provide written informed consent before any study-related activities are carried out and must be able to understand the nature and purpose of the study, including potential risks and adverse effects.
Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion Criteria

Previously received enfortumab vedotin (EV) or other MMAE-based antibody-drug conjugates (ADCs).
Received anti-cancer treatment with chemotherapy, biologics, or investigational agents within 4 weeks before the first dose of EV/pembrolizumab.
Uncontrolled diabetes.
Active CNS metastases. Participants with treated CNS metastases are permitted if all of the following criteria are met:
CNS metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis.
The participant is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least 2 weeks (if requiring steroid treatment).
The participant does not have leptomeningeal disease.
Ongoing clinically significant toxicity associated with prior treatment (including radiotherapy or surgery) that has not resolved to Grade ≤1 or returned to baseline.
History of a severe (Grade ≥3) allergic or infusion-related reaction to any monoclonal antibody.
Another underlying medical condition that, in the opinion of the investigator, would impair the ability of the participant to receive or tolerate the planned treatment and follow-up.
Known psychiatric or substance abuse disorders that would interfere with cooperating with study requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Zion?

Yes, this clinical trial (NCT07484022) has an active research site in Zion, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Urothelial Cancer Treatment Options in Zion, IL

If you're searching for advanced urothelial cancer treatment options in Zion, IL, this clinical trial (NCT07484022) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Zion research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced urothelial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced urothelial cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Zion, IL

See all bladder cancer clinical trials recruiting in Zion — not just this study.

Browse Bladder Cancer Trials in Zion →

Browse More Trials by Condition

Bladder Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Zion?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Zion, IL